223 related articles for article (PubMed ID: 20885975)
1. Portrait of ependymoma recurrence in children: biomarkers of tumor progression identified by dual-color microarray-based gene expression analysis.
Peyre M; Commo F; Dantas-Barbosa C; Andreiuolo F; Puget S; Lacroix L; Drusch F; Scott V; Varlet P; Mauguen A; Dessen P; Lazar V; Vassal G; Grill J
PLoS One; 2010 Sep; 5(9):e12932. PubMed ID: 20885975
[TBL] [Abstract][Full Text] [Related]
2. Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics.
Modena P; Lualdi E; Facchinetti F; Veltman J; Reid JF; Minardi S; Janssen I; Giangaspero F; Forni M; Finocchiaro G; Genitori L; Giordano F; Riccardi R; Schoenmakers EF; Massimino M; Sozzi G
J Clin Oncol; 2006 Nov; 24(33):5223-33. PubMed ID: 17114655
[TBL] [Abstract][Full Text] [Related]
3. Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.
Araki A; Chocholous M; Gojo J; Dorfer C; Czech T; Heinzl H; Dieckmann K; Ambros IM; Ambros PF; Slavc I; Haberler C
Acta Neuropathol Commun; 2016 Aug; 4(1):88. PubMed ID: 27550150
[TBL] [Abstract][Full Text] [Related]
4. A prognostic gene expression signature in infratentorial ependymoma.
Wani K; Armstrong TS; Vera-Bolanos E; Raghunathan A; Ellison D; Gilbertson R; Vaillant B; Goldman S; Packer RJ; Fouladi M; Pollack I; Mikkelsen T; Prados M; Omuro A; Soffietti R; Ledoux A; Wilson C; Long L; Gilbert MR; Aldape K;
Acta Neuropathol; 2012 May; 123(5):727-38. PubMed ID: 22322993
[TBL] [Abstract][Full Text] [Related]
5. Predicting which children are at risk for ependymoma relapse.
Sowar K; Straessle J; Donson AM; Handler M; Foreman NK
J Neurooncol; 2006 May; 78(1):41-6. PubMed ID: 16575538
[TBL] [Abstract][Full Text] [Related]
6. Candidate genes on chromosome 9q33-34 involved in the progression of childhood ependymomas.
Puget S; Grill J; Valent A; Bieche I; Dantas-Barbosa C; Kauffmann A; Dessen P; Lacroix L; Geoerger B; Job B; Dirven C; Varlet P; Peyre M; Dirks PB; Sainte-Rose C; Vassal G
J Clin Oncol; 2009 Apr; 27(11):1884-92. PubMed ID: 19289631
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical expression of cyclin D1 is higher in supratentorial ependymomas and predicts relapses in gross total resection cases.
de Andrade FG; Marie SK; Uno M; Matushita H; Taricco MA; Teixeira MJ; Rosemberg S; Oba-Shinjo SM
Neuropathology; 2015 Aug; 35(4):312-23. PubMed ID: 25946121
[TBL] [Abstract][Full Text] [Related]
8. Altered MicroRNA Expression Is Associated with Tumor Grade, Molecular Background and Outcome in Childhood Infratentorial Ependymoma.
Zakrzewska M; Fendler W; Zakrzewski K; Sikorska B; Grajkowska W; Dembowska-Bagińska B; Filipek I; Stefańczyk Ł; Liberski PP
PLoS One; 2016; 11(7):e0158464. PubMed ID: 27390862
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic genome-wide analysis identifies BEX1 as a candidate tumour suppressor gene in paediatric intracranial ependymoma.
Karakoula K; Jacques TS; Phipps KP; Harkness W; Thompson D; Harding BN; Darling JL; Warr TJ
Cancer Lett; 2014 Apr; 346(1):34-44. PubMed ID: 24333734
[TBL] [Abstract][Full Text] [Related]
10. Expression alterations define unique molecular characteristics of spinal ependymomas.
Lourdusamy A; Rahman R; Grundy RG
Oncotarget; 2015 Aug; 6(23):19780-91. PubMed ID: 25909290
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and microRNA profile analysis for CD44 positive expression pediatric posterior fossa ependymoma.
Shu C; Wang Q; Yan X; Wang J
Clin Transl Oncol; 2018 Nov; 20(11):1439-1447. PubMed ID: 29704232
[TBL] [Abstract][Full Text] [Related]
12. Differential expression and prognostic significance of SOX genes in pediatric medulloblastoma and ependymoma identified by microarray analysis.
de Bont JM; Kros JM; Passier MM; Reddingius RE; Sillevis Smitt PA; Luider TM; den Boer ML; Pieters R
Neuro Oncol; 2008 Oct; 10(5):648-60. PubMed ID: 18577562
[TBL] [Abstract][Full Text] [Related]
13. Ependymoma relapse goes along with a relatively stable epigenome, but a severely altered tumor morphology.
Yang D; Holsten T; Börnigen D; Frank S; Mawrin C; Glatzel M; Schüller U
Brain Pathol; 2021 Jan; 31(1):33-44. PubMed ID: 32633004
[TBL] [Abstract][Full Text] [Related]
14. Prognostic relevance of miR-124-3p and its target TP53INP1 in pediatric ependymoma.
Margolin-Miller Y; Yanichkin N; Shichrur K; Toledano H; Ohali A; Tzaridis T; Michowitz S; Fichman-Horn S; Feinmesser M; Pfister SM; Witt H; Tabori U; Bouffet E; Ramaswamy V; Hawkins C; Taylor MD; Yaniv I; Avigad S
Genes Chromosomes Cancer; 2017 Aug; 56(8):639-650. PubMed ID: 28437838
[TBL] [Abstract][Full Text] [Related]
15. TET2 promotor methylation and TET2 protein expression in pediatric posterior fossa ependymoma.
Pierscianek D; Teuber-Hanselmann S; Ahmadipour Y; Darkwah Oppong M; Unteroberdörster M; Müller O; Jabbarli R; Sure U; Zhu Y; El Hindy N
Neuropathology; 2020 Apr; 40(2):138-143. PubMed ID: 31777116
[TBL] [Abstract][Full Text] [Related]
16. DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment.
Witt H; Gramatzki D; Hentschel B; Pajtler KW; Felsberg J; Schackert G; Löffler M; Capper D; Sahm F; Sill M; von Deimling A; Kool M; Herrlinger U; Westphal M; Pietsch T; Reifenberger G; Pfister SM; Tonn JC; Weller M;
Neuro Oncol; 2018 Nov; 20(12):1616-1624. PubMed ID: 30053291
[TBL] [Abstract][Full Text] [Related]
17. Immune gene and cell enrichment is associated with a good prognosis in ependymoma.
Donson AM; Birks DK; Barton VN; Wei Q; Kleinschmidt-Demasters BK; Handler MH; Waziri AE; Wang M; Foreman NK
J Immunol; 2009 Dec; 183(11):7428-40. PubMed ID: 19917695
[TBL] [Abstract][Full Text] [Related]
18. A retrospective analysis of recurrent pediatric ependymoma reveals extremely poor survival and ineffectiveness of current treatments across central nervous system locations and molecular subgroups.
Ritzmann TA; Rogers HA; Paine SML; Storer LCD; Jacques TS; Chapman RJ; Ellison D; Donson AM; Foreman NK; Grundy RG
Pediatr Blood Cancer; 2020 Sep; 67(9):e28426. PubMed ID: 32614133
[TBL] [Abstract][Full Text] [Related]
19. p53 Pathway dysfunction in primary childhood ependymomas.
Gaspar N; Grill J; Geoerger B; Lellouch-Tubiana A; Michalowski MB; Vassal G
Pediatr Blood Cancer; 2006 May; 46(5):604-13. PubMed ID: 16086408
[TBL] [Abstract][Full Text] [Related]
20. Supratentorial and spinal pediatric ependymomas display a hypermethylated phenotype which includes the loss of tumor suppressor genes involved in the control of cell growth and death.
Rogers HA; Kilday JP; Mayne C; Ward J; Adamowicz-Brice M; Schwalbe EC; Clifford SC; Coyle B; Grundy RG
Acta Neuropathol; 2012 May; 123(5):711-25. PubMed ID: 22109108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
